Eli Lilly’s $8 billion acquisition of Loxo Oncology looks like it could pay off, with new data for RET inhibitor selpercatinib setting up a filing before the end of the year. The results of the ...

Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an $8 billion deal. Bayer first partnered with Loxo on the ...

Bayer BAYRY announced that the FDA has granted full approval to oncology drug, Vitrakvi (larotrectinib), a first-in-class TRK ...

The FDA has fully approved larotrectinib for adult and pediatric patients with solid tumors that harbor an NTRK gene fusion.